Short Information | Cue Biopharma Inc. (NASDAQ:CUE)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,771,645 |
Total Actual Volume | 11,627,857 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 88,582 |
Average Short Percentage | 19.64% |
Is there a CUE Short Squeeze or Breakout about to happen?
See the CUE Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-16-2024 | $0.9589 | $0.932 | $0.975 | $0.9205 | 280,864 | 48,005 | 17.09% |
07-15-2024 | $0.9617 | $0.93 | $1.0002 | $0.902 | 183,771 | 31,744 | 17.27% |
07-12-2024 | $0.9585 | $0.9402 | $1.0014 | $0.9338 | 309,663 | 62,382 | 20.15% |
07-11-2024 | $0.8739 | $0.9483 | $0.9568 | $0.85 | 494,451 | 69,635 | 14.08% |
07-10-2024 | $0.9771 | $0.8862 | $0.9798 | $0.8671 | 456,536 | 73,120 | 16.02% |
07-09-2024 | $0.97 | $0.93 | $0.98 | $0.93 | 328,528 | 53,251 | 16.21% |
07-08-2024 | $0.98 | $0.9769 | $1.02 | $0.93 | 543,544 | 83,843 | 15.43% |
07-05-2024 | $1 | $0.96 | $1.07 | $0.9595 | 258,168 | 48,147 | 18.65% |
07-03-2024 | $1.08 | $0.98 | $1.0867 | $0.972 | 278,275 | 59,048 | 21.22% |
07-02-2024 | $1.04 | $1.08 | $1.13 | $1.02 | 566,833 | 110,055 | 19.42% |
07-01-2024 | $1.26 | $1.02 | $1.29 | $0.9371 | 1,531,404 | 448,492 | 29.29% |
06-28-2024 | $1.41 | $1.24 | $1.4385 | $1.24 | 4,053,260 | 155,323 | 3.83% |
06-27-2024 | $1.36 | $1.4 | $1.49 | $1.34 | 267,043 | 54,538 | 20.42% |
06-26-2024 | $1.47 | $1.38 | $1.58 | $1.38 | 313,689 | 74,797 | 23.84% |
06-25-2024 | $1.46 | $1.445 | $1.47 | $1.37 | 325,907 | 67,087 | 20.58% |
06-24-2024 | $1.42 | $1.47 | $1.49 | $1.365 | 298,670 | 44,696 | 14.97% |
06-21-2024 | $1.3 | $1.35 | $1.37 | $1.26 | 331,762 | 37,860 | 11.41% |
06-20-2024 | $1.35 | $1.3 | $1.43 | $1.29 | 213,610 | 49,096 | 22.98% |
06-18-2024 | $1.33 | $1.35 | $1.42 | $1.26 | 335,971 | 91,360 | 27.19% |
06-17-2024 | $1.33 | $1.34 | $1.42 | $1.32 | 255,908 | 109,166 | 42.66% |
News, Short Squeeze, Breakout and More Instantly...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells, today provided a business and financial update for the first qua...